Editas Medicine receives approval for Phase 1/2 EDIT-401 trial, aiming for 2027 data

Editas Medicine received approval to initiate the Phase 1/2 Strive trial of EDIT-401 in Australia to treat hyperlipidemia, with plans to report initial safety data in Q1 2027.